Bain Capital Life Sciences Investors, LLC's Form 4 filing
Heartflow, Inc. (HTFL) · filed Apr 30, 2026
- Accession no.
- 0001193125-26-198593
- Filed
- Apr 30, 2026, 8:46 PM ET
- Trade date
- Apr 28-30, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market sales total $58.9M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bain Capital Life Sciences Investors, LLCCIK 0001703031 | 10% Owner |
| Bain Capital Life Sciences Fund III, L.P.CIK 0001875273 | 10% Owner |
| BCLS Fund III Investments GP, LLCCIK 0001952080 | 10% Owner |
| Bain Capital Life Sciences III General Partner, LLCCIK 0001952106 | 10% Owner |
| BCLS Fund III Investments, LPCIK 0001952107 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | Common Stock | SSaleDisposed | −254,110 | $30.51F1 | −$7,752,896.1 | 10,194,048 | Indirect | |
| Apr 29, 2026 | Common Stock | SSaleDisposed | −797,133 | $29.37F2 | −$23,411,796.21 | 9,396,915 | Indirect | |
| Apr 30, 2026 | Common Stock | SSaleDisposed | −892,533 | $29.18F3 | −$26,044,112.94 | 8,504,382 | Indirect | |
| Apr 30, 2026 | Common Stock | SSaleDisposed | −56,224 | $30.05F4 | −$1,689,531.2 | 8,448,158 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $31.46, inclusive. The reporting person undertakes to provide to Heartflow, Inc., any security holder of Heartflow, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (4) of this Form 4.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.69, inclusive.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.995, inclusive.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.19, inclusive.
Referenced by the price of 1 transaction in Table I.